Rachel Carlson

Yeah, exactly. Plus, right now, psychedelics are mostly extremely restricted, controlled drugs.

Yeah, exactly. Plus, right now, psychedelics are mostly extremely restricted, controlled drugs.

Yeah, exactly. Plus, right now, psychedelics are mostly extremely restricted, controlled drugs.

Yeah, I mean, testing whether something could potentially make a person hallucinate is really tricky, as I'm sure you can imagine. Researchers know certain receptors in our brains are involved in the hallucinogenic effect of psychedelics and ketamine. So companies like Delix are basically trying to make drugs that are like distant cousins of magic mushrooms or ketamine.

Yeah, I mean, testing whether something could potentially make a person hallucinate is really tricky, as I'm sure you can imagine. Researchers know certain receptors in our brains are involved in the hallucinogenic effect of psychedelics and ketamine. So companies like Delix are basically trying to make drugs that are like distant cousins of magic mushrooms or ketamine.

Yeah, I mean, testing whether something could potentially make a person hallucinate is really tricky, as I'm sure you can imagine. Researchers know certain receptors in our brains are involved in the hallucinogenic effect of psychedelics and ketamine. So companies like Delix are basically trying to make drugs that are like distant cousins of magic mushrooms or ketamine.

They help those trees in our brain grow new leaves, but they don't make people hallucinate. Okay, so do we know if these like non-hallucinogenic drugs work? It's definitely still up for debate, but Delix has a drug called DLX-1. It's in clinical trials now. I talked to the company's head of research and development, Eliseo Salinas.

They help those trees in our brain grow new leaves, but they don't make people hallucinate. Okay, so do we know if these like non-hallucinogenic drugs work? It's definitely still up for debate, but Delix has a drug called DLX-1. It's in clinical trials now. I talked to the company's head of research and development, Eliseo Salinas.

They help those trees in our brain grow new leaves, but they don't make people hallucinate. Okay, so do we know if these like non-hallucinogenic drugs work? It's definitely still up for debate, but Delix has a drug called DLX-1. It's in clinical trials now. I talked to the company's head of research and development, Eliseo Salinas.

He told me that the company did a clinical trial to test whether DLX-1 made people hallucinate, and it seemed like it didn't. And now they're testing the drug on patients who have depression.

He told me that the company did a clinical trial to test whether DLX-1 made people hallucinate, and it seemed like it didn't. And now they're testing the drug on patients who have depression.

He told me that the company did a clinical trial to test whether DLX-1 made people hallucinate, and it seemed like it didn't. And now they're testing the drug on patients who have depression.

And again, there's a lot more to learn. And you said other companies are doing things like this also, right? They are. Companies want to develop drugs they can patent so they can get funding for more research. So there are a bunch of groups in this space. Some are just making more traditional psychedelics.

And again, there's a lot more to learn. And you said other companies are doing things like this also, right? They are. Companies want to develop drugs they can patent so they can get funding for more research. So there are a bunch of groups in this space. Some are just making more traditional psychedelics.

And again, there's a lot more to learn. And you said other companies are doing things like this also, right? They are. Companies want to develop drugs they can patent so they can get funding for more research. So there are a bunch of groups in this space. Some are just making more traditional psychedelics.

Some are trying to make shorter acting psychedelics or engineer out potentially negative side effects, like some psychedelics bind to certain heart receptors. So they might want to take that side effect out. And all this kind of exploded around 2019, 2020, with lots of these companies popping up and eventually trying to file these patents for their respective drugs.

Some are trying to make shorter acting psychedelics or engineer out potentially negative side effects, like some psychedelics bind to certain heart receptors. So they might want to take that side effect out. And all this kind of exploded around 2019, 2020, with lots of these companies popping up and eventually trying to file these patents for their respective drugs.

Some are trying to make shorter acting psychedelics or engineer out potentially negative side effects, like some psychedelics bind to certain heart receptors. So they might want to take that side effect out. And all this kind of exploded around 2019, 2020, with lots of these companies popping up and eventually trying to file these patents for their respective drugs.

Yeah, it can get a little complicated since traditional psychedelics have been around for a really long time, and a lot of them come from nature. So I talked to a patent lawyer about this. He focuses on psychedelics. His name's Graham Pachenik.

Yeah, it can get a little complicated since traditional psychedelics have been around for a really long time, and a lot of them come from nature. So I talked to a patent lawyer about this. He focuses on psychedelics. His name's Graham Pachenik.